Dr. José Iglesias, consultant Chief Medical Officer is a biopharmaceutical industry veteran with 30 years of executive experience in all phases of oncology clinical drug development covering the areas of solid tumor oncology, immuno-oncology and translational medicineA graduate of the University of Montevideo, Uruguay, he was a pre-doctoral research fellow at the Weizmann Institute of Science (Rehovot, Israel and Duke University Medical Center (Durham, NC), working in lectin immunology, tumor surface antigens and Natural Killer (NK) cells. After graduation and 2 years in private Oncology and Hematology practice, he became a post-doctoral fellow at the University of Toronto, Canada, working on NK cells in chronic myeloid leukemia and the isolation and characterization of tumor oncofetal antigens.
Since1991, Dr. Iglesias’ career focused entirely on the biopharmaceutical industry, with his first positions being at Glaxo Canada and Adria Laboratories (Farmitalia Carlo Erba). In November 1994, he joined Eli Lilly Canada as Associate Director of Clinical Research, later being transferred to Sydney, Australia, in the role of Oncology Medical Advisor for Eli Lilly’s Australian and Asian Operations, covering the Asia-Pacific region where he established and expanded an important network of collaborations.
From 2008, and until its acquisition by Celgene, Dr. Iglesias was Chief Medical Officer at Abraxis Bioscience in Los Angeles, CA, where he was responsible for the Phase III development of Abraxane in pancreatic cancer, lung cancer and metastatic breast cancer. As result of his collaborative work, Abraxane became the new worldwide standard of care for the treatment of advanced pancreatic cancer.
Between 2012 and 2016 Dr. Iglesias was Chief Medical Officer at Bionomics, an early drug development company based in Adelaide, South Australia, and of Biothera, an immune-oncology company based in Eagan, Minnesota. In those positions, he was responsible for developing a diverse oncology pipeline, including anti-vascular agents, monoclonal antibodies, and a beta-glucan immune system modulator in melanoma and triple-negative breast cancer. From 2016 to 2018 Dr Iglesias was Vice President, Medical and Clinical Affairs at Apobiologix, a division of Apotex Inc. in Toronto, Canada, where he oversaw the global clinical development of its oncology biosimilars program and other company pipeline compounds.
Before establishing himself as an independent oncology consultant (APEX Oncology Consulting, Inc), Dr. Iglesias was VP and Head, Translational Medicine at Boston Biomedical Inc, based in Cambridge, MA. In this role, Dr. Iglesias was responsible for the clinical development of seven early pipeline compounds in immuno-oncology, solid tumor oncology, and hematologic malignancies.
Dr. Iglesias is author or co-author of more than 60 publications in the area of Oncology with over 6,000 literature citations. For a period of 5 years, he has also served as peer-reviewer for the Canadian Institutes of Health Research (Medical Research Council of Canada) within the University-Industry Program. He is an active member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR) and the European Society of Medical Oncology (ESMO).